Propanc Biopharma (PPCB)
Preclinical developer of proenzyme therapies for solid tumors.
Something off on this page? Send us feedback.
Develops the preclinical PRP proenzyme therapy for solid tumors and related recombinant research, using outsourced development before seeking a licensing partner. No approved products or product revenue exist, and PRP has yet to enter a company-sponsored controlled human trial.
Develops PRP, a preclinical fixed formulation of bovine-derived trypsinogen and chymotrypsinogen for advanced solid tumors. The planned intravenous program targets pancreatic, ovarian, and colorectal cancers and is intended to influence cancer-cell differentiation and the tumor microenvironment; it has not entered a company-sponsored controlled human trial.
Builds related research around rec-PRP/POP1, a recombinant version intended to reduce animal-source dependence and lot variability, alongside a university collaboration on senescence and fibrosis. Its Delaware parent operates from Australia, with much research conducted in the European Union through external laboratories, manufacturers, universities, and clinical-service providers.
Seeks to advance PRP through manufacturing, assay validation, regulatory authorization, and first-in-human testing before pursuing a licensing partner. Progress depends on external providers, additional financing, and regulatory approvals; commercial operations and product revenue have not begun.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $443.7K · Total debt $1.6M · Total assets $14.3M · Shareholders' equity $9.8M
- Revenue
- $0
- Operating income
- −$6.4M
- Net income
- −$6.4M
No dividends on record.
2.28M company shares as of Sep 3, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Oasis Capital, LLCStrategic | —9.99% of class, as filed | — | 13Gfiled Jul 7, 2020 ↗ |
Sylva International LLCStrategic | —9.25% of class, as filed | — | 13Gfiled Sep 8, 2021 ↗ |
Julian Norman Kenyon1Insiderdirector, officer: Chief Scientific Officer | 0.00% | 0 | Form 4filed Aug 20, 2021 ↗ |
James Andrew Nathanielsz1Insiderdirector, officer: CEO/CFO | 0.00% | 0 | Form 4filed Aug 20, 2021 ↗ |
Josef Zelinger1,2Insiderdirector | 0.00% | 0 | Form 4filed Aug 20, 2021 ↗ |
- Last filed Aug 20, 2021; leaving the company requires no filing. Not in the bar.
- Josef Zelinger reports a block also reported by James Andrew Nathanielsz; it is counted once, under James Andrew Nathanielsz.
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- AstraZeneca (ADR)
PARP therapy spans pancreatic and ovarian cancer treatment.
- Merck
PD-1 therapy targets biomarker-defined advanced colorectal cancer.
- GSK (ADR)
PARP maintenance therapy serves advanced ovarian cancer.
- AbbVie
FRα-targeted ADC serves platinum-resistant ovarian cancer.
- Eli Lilly
EGFR antibody therapy serves RAS wild-type metastatic colorectal cancer.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Propanc Biopharma | $1.02 | −0.47% | $2.3M | — | — | — | — |
| AstraZeneca (ADR) | $163.26 | +0.99% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Merck | $151.72 | +0.05% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| GSK (ADR) | $50.47 | +0.09% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| AbbVie | $264.00 | +0.88% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Median | 38.9 | 17.2 | 5.6 | +6.4% |